Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 942-925-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
In a subacute oral toxicity study in male and female rats with doses up to and including 1000 mg/kg bw/day no adverse effects were observed. Thus, the NOAEL is 1000 mg/kg bw/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study under GLP condition
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- additional control rats and additional rats dosed with 1000 mg/kg bw/day serving as recovery group because they were maintained after termination of treatment for 14 days
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 5 week
- Weight at study initiation:
males: 115.0 - 128.9 g
females: 85.6 - 109.8 g
- Fasting period before study:
- Housing: individually
- Diet ad libitum
- Water ad libitum
- Acclimation period:
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22
- Humidity (%): 50
- Air changes (per hr): 10 - 15
- Photoperiod (hrs dark / hrs light): 12 / 12 - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5 % carboxymethylcellulose
- Details on oral exposure:
- Azo zinc complex pigment melamine compound was given to male and fenale rats by gavage in doses. of 0, 100, 330, or 1000 mf/kg bw/day suspended in 0.5 % carboxymethylcellulose over a period of 28 days. For the vehicle control as well as for the high dose group extra 5 aminmals per sex were used as recovery group.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The stability and homogenicity of prepared test suspensions were confirmed by the concentration analysis validation and stability test;
tge suspension is stable for 7 days in the refrigerator and of good homogenicity. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
- Remarks:
- Doses / Concentrations:
0, 100, 330, 1000 mg/kg bw/day
Basis: - No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Azo zinc complex pigment melamine compound was given to male and fenale rats by gavage in doses. of 0, 100, 330, or 1000 mf/kg bw/day suspended in 0.5 % carboxymethylcellulose over a period of 28 days. For the vehicle control as well as for the high dose group extra 5 aminmals per sex were used as recovery group.
--Clinical signs were reported once a day
--Body weight, food consumption, detailed clinical observations, observations of open field were recorded weekly
--urine analysis, ophthalmology, sensory reactivity, grip strength and motor activity were examined in the last week, i.e. week 4, of administration period
--Hematology and blood biochemistry was evaluated at the end of the administration period
Recovery group:
--Motor activity, hematology, blood biochemistry at the end of recovery period
--Gross necropsy, organ weight, and histopathology was evaluated at the end of the administration period
Recovery group
--necdropy , organ weight were also examined at the end of recovery period - Positive control:
- no
- Observations and examinations performed and frequency:
- --Clinical signs were reported once a day
--Body weight, food consumption, detailed clinical observations, observations of open field were recorded weekly
--urine analysis, ophthalmology, sensory reactivity, grip strength and motor activity were examined in the last week, i.e. week 4, of administrationperiod
--Hematology and blood biochemistra was evaluated at the end of the administration period
Recovery group:
--Motor activity, hematologym blood biochemistry at the end of recovery period - Sacrifice and pathology:
- --Gross necropsy, organ weight, and histopathology was evaluated at the end of the administration period
Recovery group
--necdropy , organ weight were also examined at the end of recovery period - Statistics:
- Levene's test, One Way ANOVA analysis, Scheffe's multiple comparison test, Dunnett's T3 test, F test, Student t-test, Mann.whitney test
- Details on results:
- No compound related adverse effects were observed on
-- mortality and clinical signs
Evidence of coompound colored feces was noted for all dosaage group animals during the administeration period indicating that the test substance is excreted directly via feces without relevant systemic absorption. Referring to recovery group: this finding disappeared and rats recovered to normal within the 14 day period Therefore this finding is regarded to be test substance related but not as an adverse effect
No compound related adverse effects were observed on
--detailed clinical observations: behavior
--sensory reactivity assessment and grip strength
--.motor activity
Statistically significant decrease (p<0.01) was observed at the time of 50-60 min in all males of the administration group
In females of the recovery group statistically significant increase (p<0.05) was observed at the times of 10-20 and 20-30 min
These sporadic statistically significant observations at a few time intervals were not dose related and/or not consistent over time and , consequently,
not considered to be compound related
No compound related adverse effects were observed on
--body weight
--food consumption
--urine analysis
--ophthalmology
--hematological analysis
in the test animals no statistically significant difference to the control group
recovery group:
males: Platelet count (PLT) was statistically significant decreased (p<0.05) and protrombin time (PT) increased (p<0.05)
females: Monocytes percentage was statisticlaly increased (p<0.05)
As these observations were seen only in the recovery animals these observations were not regarded to be compound related
--blood biochemical analysis
in test males dosed with 1000 mg/kg bw aspartate aminotransferases (AST) was statistically significant decreased (p<0.05)
These observations were not considerd to be compound related because the observations were not dose related an/or different in different genders and not in recovery males.
No compound related adverse effects were observed at necropsy
--gross pathological evaluation
--organ weights:
-absolute organ weights
in test groups there were no adverse findings
recovery group, males thyroid gland significantly decreased (p<0.01); females no findings
-relative organ weights
in test groups no adverse findings
recovery group, males, kidneys significantly increased (p<0.05) , thyroid gland significantly decreased (p<0.01)
Since these observations were not dose dependent and/or not consistent over gender and/or only observed in recovery group they were not considered to be compound related
--no test substance related histopatholoical lesions were observed in the high dose group - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: treatment related adverse effects were not observed
- Critical effects observed:
- not specified
- Executive summary:
This study was performed to investigate the systemic toxicity on male and female rats followed 28 consecutive days repeated oral dosing of Azo zinc complex pigment - melamine compound via gavage at dose levels of 0, 100, 330, and 1000 mg/kg bw/day suspended in 0.5% carboxy methylcellulose. The study was conducted in compliance wtih OECD TG 407 under GLP conditions. In addition recovery groups (0 and 1000 mg/kg bw/day) were maintained without dosing for a further 14 days after administration period to evaluate the reversibility of any potential effects.
No animal died during the treatment period and in the recovery period thereafter. Azo zinc complex pigment - melamine compound was well tolerated. The evidence of compound colored feces was noted in all dosage groups during administration period but disappeared during recovery period. This observation indicated that absorption of Azo zinc complex pigment - melamine compound is limited. No
treatment related adverse effects could be determined during hematological and blood biochemical analysis or gross and histopathological examinations. Therefore, the NOAEL of Azo zinc complex pigment - Melamine compound is considered to be 1000 mg/kg bw/day
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- This is the only subacute study in rats which is performed according to OECD TG 407 under GLP conditions. Additionally a recovery group was added to determine the reversibility of possible effects
Additional information
This study was performed to investigate the systemic toxicity on male and female rats followed 28 consecutive days repeated oral dosing of Azo zinc complexpigment - melamine compound via gavage at dose levels of 0, 100, 330, and 1000 mg/kg bw/day suspended in 0.5% carboxy methylcellulose. Recovery groups (0 and 1000 mg/kg bw/day) were maintained without dosing for a further 14 days after administration period to evaluate the reversibility of any potential effects. The study was conducted in compliance with OECD TG 407 under GLP conditions.
No animal died during the treatment period and in the recovery period thereafter. Azo zinc complexpigment - melamine compound was well tolerated. The evidence of compound colored feces was noted in all dosage groups during administration period but disappeared during recovery period. This observation indicated that absorption of Azo zinc complexpigment - melamine compound is limited. No
treatment related adverse effects could be determined during hematological and blood biochemical analysis or gross and histopathological examinations. Therefore, the NOAEL of Azo zinc complex pigment - Melamine compound is considered to be 1000 mg/kg bw/day.Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
This is the only subacute study in rats which is performed according to OECD TG 407 under GLP conditions. Additionally a recovery group was added to determine the reversibility of possible effects. Therefore this study was evaluated with Klimisch score 1
Justification for classification or non-classification
Based on the available results from the sub-acute oral study in rats, no classification or labelling is required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
